The French drugmaker Sanofi told her that a shipping delay had interrupted supply of the drug that she relies on to manage her rare muscle-wasting disease. Her next infusion was canceled. Griffin, who is 51 and uses a wheelchair due to Pompe disease, fears what will happen if the shortage isn't resolved soon. "You're basically letting the disease take over again," she said. "It's terrifying." More than three months after initial reports of supply problems with treatments for Pompe disease, the disruption drags on, with more patients learning their infusions have been canceled. Sanofi said it has made progress restoring the supply to patients in some countries, but added that shipping delays could interrupt infusions for some U.S.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
